Friday, July 31, 2026

Expert Calls for Abandoning Regime-Change Expectations in Dealing with Pyongyang

The article suggests a paradigm shift in North Korea policy, emphasizing long-term coexistence over outdated hopes for regime change.

ARrC’s Debut: How BTS Shaped Their Journey to Stardom

At ARrC's debut, Hyunmin cited BTS as role models, admiring their growth and influence, and aspiring for similar success.

Verismo Therapeutics Welcomes FDA Approval Expert Dennis Williams: What This Means for CAR-T Cell Therapy

HLB Innovation appoints Dr. Dennis Williams as VP of Regulatory Affairs at Verismo Therapeutics to enhance global regulatory strategies.

Tag: Oncology

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Daejeon University’s Seoul Oriental Hospital Earns “Integrated Cancer Certification” – What This Means for Patients

Daejeon University's Seoul Oriental Hospital gains recognition as a Certified Integrative Cancer Center for its innovative treatment methods.

Your Guide to Jaqbo: The New GERD Treatment Shaping the Future of Chronic Care

Onconic Therapeutics begins a Phase 3 trial for Jaqbo, aiming to expand GERD treatment options and enhance long-term management strategies.

LG Chem’s FMC-220: A Breakthrough Cancer Drug Targeting the p53 Y220C Mutation

LG Chem secures exclusive rights to FMC-220, a cancer drug targeting the p53 Y220C mutation, aiming for Phase 1 trials.

Verismo Therapeutics Welcomes FDA Approval Expert Dennis Williams: What This Means for CAR-T Cell Therapy

HLB Innovation appoints Dr. Dennis Williams as VP of Regulatory Affairs at Verismo Therapeutics to enhance global regulatory strategies.

SK Biopharm’s 2026 Sales Meeting: Key Strategies for Senolamate’s Global Success

SK Biopharm's U.S. subsidiary held its annual sales meeting, focusing on growth strategies and collaboration for Cenobamate's success.

Hanmi Posts Record $1.16B Sales and $193M Operating Profit: What’s Driving the 2025 Surge

Hanmi Pharmaceutical reports record sales of $1.16 billion in January 2025, with significant growth in profits and new product launches.

HLB’s Liragratinib: A Game-Changer in Cholangiocarcinoma Treatment Revealed at ASCO GI 2026!

HLB's lirafugratinib shows promise as a precision oncology drug, targeting FGFR2 in cancer treatment. FDA application expected soon.

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

J&J Aims to Treat Cancer Before It Starts Showing Symptoms

Johnson & Johnson leads in multiple myeloma treatment, pioneering early intervention for high-risk patients with a new subcutaneous formulation.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.